title: [Combined application of cisplatin and celecoxib inhibits the proliferation and promotes apoptosis of nasopharyngeal carcinoma cells resistant to cisplatin].
abstract: OBJECTIVE
  To investigate the synergistic cytotoxicity of cis-dichlorodiamine platinum (DDP) and celecoxib on nasopharyngeal carcinoma TW03 cell which is resistant to DDP (TW03/DDP).
  
  
  METHODS
  The mRNA and protein levels of lung resistance-related protein (LRP) were detected by reverse transcription PCR and Western blotting in TW03/DDP cells after (0.05-1.00) μg/mL DDP treatment. TW03/DDP clone which highly expressed LRP was transfected with siRNA targeting LRP mRNA. Nasopharyngeal carcinoma TW03 cells, TW03/DDP cells and TW03/DDP-siRNA cells were treated respectively with DDP or celecoxib or combination of the two. CCK-8 assay was performed for detecting proliferation. Annexin V-FITC/PI staining combined with flow cytometry were used for detecting apoptosis rate.
  
  
  RESULTS
  Both DDP and celecoxib treatment inhibited the proliferation and induced the apoptosis of TW03 cells and TW03/DDP cells, but only celecoxib showed a significant effect on TW03/DDP cells, but not DDP. Combination of DDP and celecoxib showed a synergistic role in inducing the apoptosis of both TW03 cells and TW03/DDP cells. Meanwhile, LRP mRNA and protein levels were down-regulated in celecoxib-treated TW03/DDP cells.
  
  
  CONCLUSIONS
  DDP and celecoxib showed a synergistic effect on proliferation inhibition and apoptosis induction of TW03/DDP cells by down-regulating LRP mRNA and protein levels.
authors: Department of Medical Affairs, Neijiang First People's Hospital, Neijiang 641000, China.
authors: Jianjun
authors: J
authors: Chen
authors: Department of Ear, Nose and Throat, West China Hospital, Sichuan University, Chengdu 610065, China.
authors: Shixi
authors: S
authors: Liu
authors: Department of Medical Affairs, Neijiang First People's Hospital, Neijiang 641000, China.
authors: Qijun
authors: Q
authors: Li
authors: Department of Medical Affairs, Neijiang First People's Hospital, Neijiang 641000, China.
authors: Jie
authors: J
authors: Peng
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D002277:Carcinoma; D000068579:Celecoxib; D049109:Cell Proliferation / Q000187:drug effects*; D002945:Cisplatin / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology*; D011720:Pyrazoles / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology*; D020394:Vault Ribonucleoprotein Particles / Q000235:genetics / Q000378:metabolism; D000099187:Major Vault Protein
chemical_list: D000970:Antineoplastic Agents; D000068579:Celecoxib; D002945:Cisplatin; D011720:Pyrazoles; D013449:Sulfonamides; D020394:Vault Ribonucleoprotein Particles; D000099187:Major Vault Protein